Every 10-Q that AnaptysBio, Inc. (ANAB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ANAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANAB filings page.
AnaptysBio reports a royalty-focused Q1 2026 with a wider loss as it prepares for a spin-off of its drug development business. Collaboration revenue was $25.6 million, entirely from non-cash royalties on GSK’s Jemperli and Zejula. Research and development expense fell to $34.0 million as late-stage programs wound down, while general and administrative costs rose to $26.2 million, driven by legal spending and separation-related costs.
The company recorded a net loss of $52.9 million and significant non-cash interest expense of $20.9 million on royalty monetization liabilities tied to Jemperli and Zejula. Cash, cash equivalents and investments totaled $286.5 million as of March 31, 2026, and management believes this will fund operations for at least 12 months. On April 20, 2026, after quarter-end, AnaptysBio completed the spin-off of First Tracks Biotherapeutics, retaining a royalty-management focus around Jemperli and its imsidolimab collaboration with Vanda.
AnaptysBio (ANAB) reported stronger Q3 results and outlined a potential separation. For the three months ended September 30, 2025, collaboration revenue reached $76.3 million, driven by GSK-related royalties and milestones, while operating expenses were $41.6 million. Income from operations was $34.7 million, and net income was $15.1 million (diluted EPS $0.52).
The company recognized a $50.0 million Jemperli sales milestone in Q3 and recorded royalty revenue of $26.3 million. Non‑cash interest expense tied to royalty monetizations was $22.5 million in Q3. Cash and cash equivalents were $109.8 million, with short‑term investments of $139.1 million. A liability related to the sale of future royalties totaled $331.8 million, and stockholders’ equity stood at a $29.4 million deficit. The company repurchased 3.34 million shares for $65.2 million, leaving $9.8 million authorized.
Strategically, the Board approved exploring a separation into two public companies: one focused on managing GSK/Vanda milestones and royalties, and another advancing immunology programs including rosnilimab, ANB033 and ANB101, with completion targeted by year‑end 2026, subject to approvals.